COMPOSITIONS COMPRISING BACTERIAL STRAINS
The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.
1 .- 34 . (canceled)
35 . A pharmaceutical composition comprising a bacterial strain of the genus Roseburia in a therapeutically effective amount for reducing a level of a proinflammatory cytokine in a subject when administered to the subject, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein:
(a) the bacterial strain is lyophilized,
(b) the pharmaceutical composition does not comprise a therapeutically effective amount of any other strain, and
(c) the pharmaceutical composition is formulated in an enteric capsule for delivery to an intestine of the subject.
36 . The pharmaceutical composition of claim 35 , wherein the proinflammatory cytokine is interleukin 6 (IL-6).
37 . The pharmaceutical composition of claim 35 , wherein the therapeutically effective amount comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU).
38 . The pharmaceutical composition of claim 35 , wherein the pharmaceutical composition comprises from about 1×10 6 to about 1×10 11 colony forming units per gram (CFU/g), with respect to the weight of the pharmaceutical composition.
39 . The pharmaceutical composition of claim 35 , wherein the bacterial strain is of the species Roseburia hominis, Roseburia intestinalis , or Roseburia faecis.
40 . The pharmaceutical composition of claim 35 , wherein the bacterial strain comprises a 16S rRNA gene sequence that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:3, SEQ ID NO: 5, or SEQ ID NO:6.
41 . The pharmaceutical composition of claim 35 , wherein the bacterial strain comprises a 16S rRNA gene sequence that has at least 98% sequence identity to the polynucleotide sequence of SEQ ID NO:3, SEQ ID NO: 5, or SEQ ID NO:6.
42 . The pharmaceutical composition of claim 35 , wherein the bacterial strain comprises a 16S rRNA gene sequence of SEQ ID NO:3, SEQ ID NO: 5, or SEQ ID NO:6.
43 . The pharmaceutical composition of claim 35 , wherein the bacterial strain is the strain deposited under accession number NCIMB 42383, the strain deposited under accession number NCIMB 43043, or a biotype thereof.
44 . The pharmaceutical composition of claim 43 , wherein the biotype is a bacterial strain that has the same carbohydrate fermentation pattern as the strain deposited under accession number NCIMB 42383 or the strain deposited under accession number NCIMB 43043.
45 . The pharmaceutical composition of claim 35 , wherein the bacterial strain is capable of at least partially colonizing an intestine of the subject.
46 . The pharmaceutical composition of claim 35 , wherein the pharmaceutical composition is formulated for oral administration.
47 . The pharmaceutical composition of claim 35 , wherein the bacterial strain is live.
48 . A pharmaceutical composition comprising a bacterial strain of the genus Roseburia in a therapeutically effective amount for reducing a level of the NFκB promoter activation in a subject and a pharmaceutically acceptable excipient, diluent, or carrier, wherein:
(a) the bacterial strain is lyophilized,
(b) the pharmaceutical composition does not comprise a therapeutically effective amount of any other strain, and
(c) the pharmaceutical composition is formulated in an enteric capsule for delivery to an intestine of the subject.
49 . A method of treating a neurodegenerative disorder in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of a bacterial strain of the genus Roseburia , wherein the bacterial strain comprises a 16S rRNA gene sequence that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:3, SEQ ID NO: 5, or SEQ ID NO:6, and wherein the administering is effective to treat the neurodegenerative disorder.
50 . The method of claim 49 , wherein the administering is effective to reduce a level of a proinflammatory cytokine in the subject.
51 . The method of claim 49 , wherein the proinflammatory cytokine is interleukin 6 (TL-6).
52 . The method of claim 49 , wherein the therapeutically effective amount comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU).
53 . The method of claim 49 , wherein the composition comprises no more than de minimis amounts of other bacterial strains.
54 . The method of claim 49 , wherein the composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier.